Oct. 25 (Bloomberg) -- TiGenix NV got approval from the independent Safety Monitoring Board to move its Phase IIa clinical trial in rheumatoid arthritis into randomized recruitment.

“This decision is based on the analysis of the safety data from patients treated in the study’s first cohort,” TiGenix said today in an e-mailed statement.

To contact the editor responsible for this story: Andrew Clapham at aclapham@bloomberg.net